Sanofi - Aventis Groupe: Press Release: Dupixent (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis

Dupixent (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis Approval based on direct-to-Phase 3 program showing

Related Keywords

Japan ,Paris ,France General ,France ,Eva Schaefer Jansen ,Corentine Driancourt ,Felix Lauscher ,Sharon Chen ,Georged Yancopoulos ,Vesna Tosic ,Nathalie Pham ,Sally Bain ,Naimish Patel ,Priya Nanduri ,Regeneron Pharmaceuticals Inc ,Twitter ,Regeneron Genetics Center ,European Commission ,Dupilumab Development Program ,Nasdaq ,Exchange Commission ,European Union ,Head Of Global Development ,Euronext ,Global Development ,Chief Scientific Officer ,Dupixent Prurigo ,Worst Itch Numeric Rating Scale ,Global Assessment ,Dermatology Life Quality Index ,Numerical Rating Scale ,Hospital Anxiety ,Depression Scale ,Regeneron Genetics ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Forward Looking Statements ,Digital Media ,Regeneron Pharmaceuticals ,Product Candidates ,Sanofi ,Eventis ,Roupe ,Dress ,Release ,Dupixent ,Dupilumab ,Approved ,European ,Commission ,First ,Only ,Argeted ,Medicine ,Syndicated ,Prurigo ,Nodularis ,